BeiGene
BGNE
#934
Rank
NZ$35.98 B
Marketcap
$323.48
Share price
-2.10%
Change (1 day)
-0.77%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total debt

Total debt on the balance sheet as of June 2024 : NZ$1.86 Billion

According to BeiGene 's latest financial reports the company's total debt is NZ$1.86 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BeiGene - Total debt on balance sheet (from 2014 to 2024)

Total debt by year

Year Total debt Change
2023-12-31NZ$1.47 B56.51%
2022-12-31NZ$0.93 B-7.59%
2021-12-31NZ$1.01 B30.58%
2020-12-31NZ$0.77 B89.13%
2019-12-31NZ$0.41 B39.23%
2018-12-31NZ$0.29 B27.53%
2017-12-31NZ$0.23 B829.49%
2016-12-31NZ$24.95 M-17.84%
2015-12-31NZ$30.37 M71.96%
2014-12-31NZ$17.66 M-46.96%
2013-12-31NZ$33.29 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.46 B-75.28%๐Ÿ‡บ๐Ÿ‡ธ USA